+281.4%
FSLR vs MRNA
+878.5%
-597.1%
-60.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.2% | -3.6% | -1.6% | -5.0% |
| 7D | -15.2% | -20.0% | +4.8% | -14.1% |
| 30D | -5.9% | -1.3% | -4.6% | -6.0% |
| 3M | -28.0% | +240.0% | -268.0% | -36.1% |
| 6M | -30.4% | +339.0% | -369.4% | -40.1% |
| YTD | -37.8% | +630.0% | -667.8% | -49.6% |
| 1Y | -35.8% | +769.1% | -804.9% | -48.9% |
| 3Y | +5.1% | +181.2% | -176.1% | -8.8% |
| 5Y | +55.5% | -8.1% | +63.6% | +40.7% |
| All | +281.4% | +878.5% | -597.1% | +247.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling